Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells

Maria Corinna Palanca-Wessels(Unknown), Oliver W. Press(Fred Hutch Cancer Center)

Oncotarget

January 30, 2016

10.18632/oncotarget.7076

Cited by 49

Related Papers

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

|Blood|2008|719

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

|The Lancet|2017|580

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

|Blood|2012|530

Non-Hodgkin’s Lymphomas

|Journal of the National Comprehensive Cancer Network|2010|329

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

|PubMed|1996|212